The binding of factor Vlll t o von Willebrand factor (vWF) is essential for the protection of factor Vlll against proteolytic degradation in plasma. We have characterized the binding kinetics of human factor VIII with vWF using a centrifugation binding assay. Purified or plasma vWF was immobilized with a monoclonal antibody (MoAb RU1) covalently linked to Sepharose (Pharmacia LKB Biotechnology, Uppsala, Sweden). Factor Vlll was incubated with vWF-RU1-Sepharose and unbound factor Vlll was separated from bound factor Vlll by centrifugation. The amount of bound factor Vlll was determined from the decrease of factor Vlll activity in the supernatant. Factor Vlll binding to vWF-RU1-Sepharose conformed to the Langmuir model for independent binding sites with a K, of 0.46 k 0.12 nmol/L, and a stoichiometry of 1.3 factor Vlll molecules per vWF monomer at saturation. suggesting that each vWF subunit contains a binding site for factor VIII. Competition experiments were performed with a recombinant vWF (AM-rvWF), lacking residues 730 to 910 which contain the epitope for MoAb RU1. AA2-rvWF effectively displaced previously bound factor VIII, confirming that ACTOR VI11 plays an essential role in the intrinsic path-F way of blood coagulation as cofactor for factor IXa in the activation of factor X in the presence of Ca" and phospholipids. Qualitative or quantitative deficiencies of factor VI11 cause bleeding tendencies characteristic of hemophilia A. This condition is inherited as a sex-linked recessive trait, affecting approximately 1 in 10,000 males.' Factor VIII circulates in plasma at a concentration of 0.2 p g / d (~1 nmol/L),' and is bound to its carrier protein von Willebrand factor (vWF) by both hydrophobic and electrostatic interact i o n~.~ vWF, which is an adhesive glycoprotein that facilitates adhesion of platelets to the injured vessel circulates at approximately 10 p g / d , I and comprises a series of disulfide-bonded multimers ranging in size from dimers of approximately 500 kD to species of more than 20 million daltom6
The liver is generally believed to be the major site of factor VI11 synthesis, although factor VIII " A has been detected in many other cells and tissues as well.' vWF is synthesized in endothelial and is secreted constitutively, or stored in intracellular organelles known as WeibelPalade bodies.8 vWF is also synthesized in megakaryocytes and stored in a-granules of platelets.' Thus, both glycoproteins are synthesized at different sites, and complex formation probably occurs in the plasma.
The binding of factor VI11 to vWF is essential for the survival of factor VIII in the circulation. In either normal individuals or patients with hemophilia A, the half-life of transfused factor VIII is approximately 12 hours, and the clearance of factor VI11 is indistinguishable from that of either vWF or preformed factor VIII-vWF complex." However, in patients with severe von Willebrand disease (vWD) the lack of stabilization of factor VIII by binding to vWF causes a decrease of factor VIII." Similarly, a functional defect in the factor VI11 binding domain of vWF (in vWD type Normandy or type 2NL2) results in an accelerated clear- ance of factor VIILL3 In previous studies, it was shown that vWF protects factor VI11 from activated protein C-catalyzed inactivation,14 and that vWF prevents activation of factor VI11 by activated factor X.I5.l6 Factor VI11 binds to vWF via its light chain" with high affinity (& = 0.2 to 0.4 nmoY L).l8." In vitro, a stoichiometry of 1:l (molecules of factor VI11 per subunit of vWF) was found.20 In vivo, however, vWF apparently circulates with many unoccupied binding sites because the molar concentrations of both proteins indicate a 50-fold excess of VW in plasma. Although equilibrium binding data exist, little information is available regarding the kinetics of the factor VIII-vWF interaction. Leyte et all8 reported a first-order dissociation rate constant of 0.9 X s-', obtained by means of solid-phase binding experiments. However, no rate constant of association was reported.
In this report, we describe a binding assay using vWF coupled to Sepharose with a monoclonal antibody (MoAb) that allows rapid separation of bound and free factor VI11 by centrifugation. Using this assay, we characterized the kinetics of factor VI11 binding to vWF.
MATERIALS AND METHODS
All experiments were performed at 22°C in 150 mmol/L NaCI, 50 mmoVL TRIS-HCI, pH 7.4, containing 0.1% Tween-20 (E. Merck AG, Darmstadt, Germany), 1% bovine serum albumin fraction V (Sigma Chemical CO, St Louis, MO), and 2 mmoVL CaCI, (TBS), unless indicated otherwise. Centrifugation steps were performed in an Eppendorf microfuge at 10,000g for 10 seconds.
Recombinant factor VI11 was a generous gift from Dr R.J. Kaufman (Genetics Institute, Cambridge, MA). This preparation was essentially free of vWF as measured with an enzyme-linked immunosorbent assay (ELISA). Human vWF devoid of factor VI11 was purified from human cryoprecipitates (kindly provided by A. Knevelman and H.J.C. de Wit from the Red Cross Blood Bank Friesland, Leeuwarden, The Netherlands) using gel-filtration chromatography as described previously.16,2' Fractions were collected and assayed for vWF:Ag, vWF:Ag multimers and factor VI11 activity. The first fractions contained high multimers, followed by intermediate and low multimeric vWF. Fractions were pooled and stored at -70°C until use, except for the experiments with high and low multimeric vWF, where fractions were not pooled and stored separately.
A detailed description of the construction and expression of a recombinant vWF, which lacks the A2 repeat (residues 730 to 910) in baby hamster kidney cells will be published elsewhere (Lankhof H, et al, submitted). Briefly, site-directed mutagenesis was used to delete the coding region for the A2 domain, and the deletion construct was cloned in the pNUT-expression vector." After transfection, stable cell lines were selected with methotrexate. AA2-rvWF was purified from serum-free medium with affinity chromatography techniques, and showed a full range of vWF:Ag multimers on gel electrophoresis and ristocetin-induced platelet aggregation, equivalent to normal plasma.
Blood from 40 healthy donors was collected in one-tenth volume of 3.8% trisodium-citrate. After centrifugation at 1,200g for 15 minutes at 4"C, the plasma was pooled and stored at -70°C until use. In addition, plasma from three patients with severe hemophilia A was obtained, containing less than 1% factor VI11 activity, and normal vWF:Ag and ristocetin cofactor activity levels.
MoAb RUI directed against the A2 repeat of human vWF was prepared in our laboratory." vWF concentrations were determined with an ELISA using nonconjugated and peroxidase-conjugated polyclonal rabbit antibodies against human vWF (Dakopatts, Glostrup, Denmark), with normal pooled plasma as a standard. The multimeric structure was assayed using the Pharmacia Phast Gel System (Pharmacia LKB Biotechnology, Uppsala, Sweden) as described.*' Factor VI11 concentrations were determined by using a chromogenic substrate assay (Factor VI11 Coatest; Chromogenix, Molndal, Sweden).24 The change in absorbance at 405 nm was measured using a V-max reader (Molecular Devices Corp, Menlo Park, CA). Normal pooled plasma was used as a reference. The concentrations of factor VIII and vWF in normal pooled plasma were taken from literature as 0.2 pg/mL* and 10 pg/mL,' respectively. The molecular weights used to determine concentrations were as follows: factor VIII, 240,000; purified and plasma vWF monomer, 270,000; and AA2-rvWF monomer, 250,000.
Preparation of RUl-Sepharose. MoAb RUI was coupled to cyanogen bromide-activated Sepharose CL-4B (Pharmacia LKB Biotechnology, Uppsala, Sweden) to a final concentration of 1 mg MoAb Proteins.
Production of a deletion variant vWF (AA2-rvWF).
Plasma vWF.
Antibodies.

Quant$cation of proteins.
RU l/mL of Sepharose, according to the manufacturer's instructions. After coupling and blocking of residual active sites, RU 1 -Sepharose was incubated for 30 minutes with TBS containing 4% bovine serum albumin to prevent nonspecific binding. vWF was added to a 50% suspension of RU1-Sepharose in a final volume of 1 mL and allowed to bind. During incubation the sample was mixed and after 1 hour the vWF-RUI -Sepharose was washed five times by resuspension and repeated centrifugation in TBS.
Factor VI11 (150 pL) was incubated with vWF-RUI-Sepharose (50 pL; 50% suspension in TBS). During incubation the tubes were mixed by inversion. After IO to 600 seconds, the factor VI11 bound to vWF-RU1-Sepharose and unbound factor VI11 were separated by centrifugation and the factor VlIl concentration in the supernatant was measured. Initial experiments performed at 22°C and 37°C yielded similar rate constants, thus subsequent experiments were performed at 22°C.
Because AA2-rvWF lacks the epitope for MoAb RU1, it cannot compete with vWF for binding to RUlSepharose. vWF-RU1-Sepharose (100 pL; 50% suspension in TBS) was incubated with factor VI11 (100 pL) for 30 minutes, and then AA2-NWF (200 pL; final concentration 0 to 35 nmol/L) was added. After 2 hours, the samples were centrifuged and the supernatants were tested for factor VI11 activity.
The dissociation rate constant (kc,,,) for the factor VIII-vWF complex was determined in dilution experiments. Factor VI11 (15 pL) was added to vWF-RUI-Sepharose (250 pL, 50% suspension in TBS) and mixed. After 30 minutes, the mixture was diluted 50-fold by adding TBS. At different time intervals, 300-pL aliquots containing buffer and Sepharose beads were removed, centrifuged, and the supernatant was assayed for factor VI11 activity.
Dura analysis. Equilibrium binding data of factor VI11 to vWF-RU1-Sepharose were analyzed by the Langmuir model for independent binding sites:
Association experiments.
Competition experiments.
Dissociation experiments.
FVIIb. c,, = c m a x Kd + FVIIIfm, with C,, the amount of factor VI11 bound to vWF-RU1-Sepharose, C , , the maximal binding capacity of the vWF-RU1-Sepharose, Kd the dissociation constant, and FVIIIf,ee the concentration of unbound factor VIII. It should be noted that this model does not take into account the possibility that the adjacent binding sites on the multimeric vWF interact. Application of this model to binding data obtained for various factor VI11 concentrations and a fixed vWF concentration allowed establishment of the binding stoichiometry and of the dissociation constant.
In competition experiments the nonsedimentable fraction of factor VI11 (FVIIIns) of total added factor VI11 (FVIIb) was measured as function of the AA2-rvWF concentration. In this situation the binding of factor VI11 to vWF-RUl-Sepharose is again described by Equation 1, whereas the binding to AA2-rvWF is described by a similar equation:
where C,,,,,, is the maximal binding capacity of AA2-rvWF and Kd,,* is the dissociation constant for factor VI11 binding to AA2-rvWF. These experiments were performed in the presence of high concentrations vWF. As a result the concentration of unbound factor VIII, FVIIIfc, was far below the Kd and Equations ( I ) and (2) can be simplified to:
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RESULTS
Binding of vWF and factor VIII to RUI-Sepharose. The concentration of vWF bound to RUl-Sepharose was determined by measuring the vWF concentrations in the supematant after incubation with RU1-Sepharose, and by subtracting these values from the amount initially present in the incubation mixture. Typically, 70% to 80% of added vWF bound to RUl-Sepharose under these conditions, and no vWF release could be measured after subsequent washing steps. Identical binding was found for purified and plasma vWF.
Aspecific binding of factor VI11 could result in an overestimation of factor VI11 binding. However, in control experiments where factor VI11 was added to RUl-Sepharose we observed more than 98% recovery of factor VIII, which indicated that aspecific binding was less than 2% and was therefore considered to be negligible. In preliminary experiments, factor VI11 (0.5 nmol/L) was added to an excess of vWF-RU1-Sepharose. After 30 minutes, samples were centrifuged and supematants were assayed for factor VI11 activity. The amount of factor VI11 remaining in the supematant was 8.8% ? 2.6% (mean ? SD, n = 4) of the initial amount. This factor VI11 also did not bind to newly added vWF-Sepharose, and therefore most likely represents activated factor VI11 that does not bind to vWF but is normally detected in the chromogenic assay. We corrected for this fraction of nonbinding factor VI11 in the data analysis.
To determine whether the affinity of vWF for factor VI11 was affected by binding of vWF to RU1-Sepharose, increasing amounts of factor VI11 were incubated with a constant amount of vWF-RUI-Sepharose (2.1 nmol/L) for 30 minutes and the time course of binding was followed until equilibrium was reached. The concentration of bound factor VI11 was obtained by subtracting the equilibrium value of unbound factor VI11 from the total added factor VI11 concentration. Figure 1 shows that factor VI11 binds to vWF-RUl-Sepharose in a dosedependent saturable manner. An adequate fit to these data was obtained using the model for (identical) independent binding sites given in Equation To compare factor VI11 binding to solution-phase vWF and to vWF immobilized to RU1-Sepharose, competition experiments were performed in which a vWF mutant was incubated with preformed factor VIII-vWF-RU 1 -Sepharose complexes. The mutant (AA2-rvWF) was chosen because it lacks the A2 domain (residues 730 to 910) that contains the epitope for MoAb RU1, and therefore does not bind to MoAb RU1. First, factor VI11 (0.16 nmol/L) was incubated with vWF-RU1-Sepharose (vWF concentration 8.0 nmol/L) for 30 minutes. Then AA2-rvWF (0 to 35 nmol/L) was added, and after 2 hours of incubation, the samples were centrifuged and the factor VI11
Equilibrium binding isotherm.
Studies with AA2-rvWF. Equilibrium binding results were compatible (see Fig I) , with one independent factor VI11 binding site per vWF subunit. Therefore, binding kinetics were modeled as a simple reversible bimolecular association reaction:
where C represents the factor VIII-vWF complex and k,, and koff are the association and dissociation rate constants for the reaction. These constants are related to the dissociation constant Kd = koff/ ken. The rate of change of the concentration of the factor VIII-vWF complex with time is given by the differential equation:
with FVMo and vWFo the total added factor VI11 and vWF monomer concentrations. The concentration of factor VIII-vWF complexes at equilibrium, C , , expressed in terms of FVIII,, and vWFO, is given by:
The solution of Equation 4 is given by:
where CO represents the initial concentration of FVIII-vWF complexes, and For activity in the supernatant was measured. This activity represents the sum of unbound factor VI11 and factor VI11 bound to AA2-rvWF. Control experiments indicated that the presence of AA2-rvWF did not interfere with cofactor activity of factor VI11 in the chromogenic assay used (data not shown). Figure 2 shows that addition of AA2-rvWF resulted in a dose-dependent increase of the factor VI11 concentration in the supernatant. By a least-squares fit of Equation 3 to the data, using the binding parameters for vWF-RUl -Sepharose determined in Fig 1, a dissociation constant of 0.32 +-0.04 nmol/L was found. This result provides further evidence that factor VI11 binding to vWF-RU 1 -Sepharose is reversible, and that immobilizing vWF via an MoAb to Sepharose does not alter the binding affinity for factor VIII.
The rate of factor VIII-vWF complex formation was determined by incubating factor VI11 with vWF-RU1-Sepharose for various time intervals, and by assaying the concentration of unbound factor VI11 in the supernatant. Initial concentrations of factor VI11 and vWF were chosen so that complex formation was slow enough to be followed in time, ie, with concentrations below the plasma concentrations for both factor VI11 and vWF. Figure 3 Factor VI11 was incubated with purified vWF coupled to RU1-Sepharose for 10 to 600 seconds. Concentrations varied from 0.34 to 0.52 nmol/L and 1.5 to 6.0 nmol/L for factor VI11 and vWF, respectively. Unbound and bound factor VI11 were separated by centrifugation, and the concentration of unbound factor VI11 in the supernatant was measured with a chromogenic assay. Kinetic rate constants were derived by a least squares fit of Equation 6 to the data. The values are indicated as mean t SD of three experiments performed in duplicate.
a constant amount of RU1-Sepharose and incubated with a low (0.02 nmol/L) or high (0.34 nmol/L) factor VI11 concentration. As expected, the rate of complex formation increased with increasing factor VIII and vWF concentrations, whereas the estimated rate constants were similar (knn = 5.2 and 4.3 x lo6 M-' s-' and knff = 3.9 and 2.2 X s-', respectively). This indicates that the model of bimolecular association (Scheme 1) provides adequate description and that complex formation is not influenced by a transport rate limitation.
The purified v W F used in the preceding experiments contained a mixture of high and low vWF multimers, as present in plasma. To investigate the influence of multimeric size of vWF on the rate of complex formation, vWF subfractions containing only high or low multimers were used to immobilize vWF to RUl-Sepharose, and association experiments were performed. Binding of high and low multimeric v W F to RU1-Sepharose was similar (data not shown). Table 1 shows that similar values were found for the rate constants of association and dissociation, indicating that factor VIIIv W F interaction is independent of the degree of vWF multimerization .
Because the coupling of vWF to RU1-Sepharose is followed by a washing procedure, it also permits selective binding of vWF from plasma. We performed binding experiments with vWF from normal pooled plasma and from plasma from patients with severe hemophilia A. As shown in Table 2 vWF from normal pooled plasma or from plasma from patients with severe hemophilia A was coupled to RU1-Sepharose and incubated with factor Vlll for 10 to 600 seconds. Concentrations varied from 0.36 to 0.56 nmol/L and 1.3 to 3.1 nmol/L for factor VI11 and vWF, respectively. Assays were performed and data were analyzed as described in the legend to Table 1 . The values are indicated as mean t SD of three experiments performed in duplicate. vWF from normal pooled plasma and from plasma of patients with severe hemophilia A exhibits kinetic rate constants comparable to purified vWF.
The dissociation rate constant of factor VIII binding to vWF-RU1-Sepharose was determined independently by dilution of preformed factor VIIIvWF-RU1-Sepharose complexes, prepared by incubation of factor VI11 (1.6 nmol/L) with vWF-RU1-Sepharose (vWF concentration 7.7 nmoyL). The dilution (50-fold) was chosen so that the concentration of factor VI11 decreased to below the dissociation constant of the factor VIII-vWF complex (Kd -0.4 nmol/L, see Fig 1) . Figure 4 shows that the simple bimolecular association model (Scheme 1, Equation 6) provides an excellent fit to these data. The fit resulted in a dissociation rate constant, kOn = 0.91 ? 0.24 X s-' (mean ? SD, n = 4), which is in good agreement with the value k,, = 1.6 X s-' obtained in the association experiments. Similar experiments with vWF from normal pooled plasma or from patients with severe hemophilia A yielded equivalent results (data not shown).
Dissociation experiments.
DISCUSSION
In the present study we developed a method that allowed the measurement of the association and dissociation kinetics of the factor VIII-vWF complex with a time resolution of 15 seconds. vWF was immobilized by binding to an MoAb (MoAb RU1) coupled to Sepharose beads. Free factor VI11 and factor VI11 associated with vWF bound to the Sepharose could be separated by centrifugation. The data presented here show that factor VIII-vWF complex formation is a rapid For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From process with an association rate constant of 5.9 t 1.9 x 10' M-' s-' and a dissociation rate constant of 1.6 t 1.2 x lo-? s-'. In addition, we found identical rate constants for vWF from normal pooled plasma and from plasma of patients with hemophilia A.
The dissociation constant, Kd = 0.46 t 0.12 nmoVL, found in equilibrium experiments, was in good agreement with the Kd values for the factor VIII-vWF interaction previously reported by us2' and other^.'^.'^^^^ The stoichiometry found in this study is consistent with the value of 1: 1 (molecules of factor VI11 per subunit of vWF) reported by Lollar et a1," who analyzed the interaction between the corresponding porcine proteins. It is also consistent with the value that we found previously in experiments with vWF conjugated to 15-nm colloidal gold." In experiments with vWF immobilized directly or indirectly via an antibody on the wells of a microtiter plate, a different stoichiometry of 150 to 1:lOO was found.'8.2', 26 We previously observed that in solution, vWF binding to MoAbs with epitopes distinct from the factor VI11 binding region per se does not interfere with the 1:l stoichiometry of factor VI11 binding." Therefore, it appears that binding of vWF directly to a plastic surface or indirectly via an MoAb causes steric restrictions, which then results in a loss of factor VI11 binding capacity of the majority (98% to 99%) of the vWF subunits. However, in this study all vWF subunits retained their binding capacity when bound to Sepharose with an antibody, and the value of Kd found in competition experiments (see Fig 2 ) indicates that binding of vWF to RU1-Sepharose does not significantly affect the affinity of vWF for factor VI11 binding.
The observed association and dissociation kinetics were adequately described by assuming one single class of binding sites for factor VI11 and vWF. The value k,, = 5.9 t 1.9 X 10' M-' s-' found for the association rate constant of the factor VIII-vWF complex is well below the diffusion limit of lo9 M-' s-', and typical for protein-protein reactions in solution. The value kOff = 1.6 t 1.2 X lo-' s-' for the first-order rate constant of dissociation and the half-life of dissociation of 430 seconds found in this study agrees well with the results from Leyte et a1,I8 who reported a first-order dissociation rate constant of 0.9 X lo-' s-' and a half-life of dissociation of 780 seconds. The dissociation of bound factor VI11 from vWF-RU1-Sepharose in exchange experiments with AA2-rvWF supports the reversibility of the factor VIII-vWF interaction. It also indicates that factor VI11 can dissociate from vWF in the presence of an excess of vWF, and in the absence of thrombin. This is consistent with our previous observation in vivo, in which radiolabeled factor VI11 in complex with lower multimeric vWF was redistributed over all multimeric forms of vWF after infusion into patients with hemophilia A."
The assay used in this study showed no difference in factor VIII-vWF binding kinetics between low and high multimeric vWF. Likewise, the calculated values for the dissociation constants were similar. This extends our earlier observation that both forms of vWF have the same affinity toward factor VI11 (Koppelman S, et al, Blood, in press). It is important to note that vWF was bound to RUl-Sepharose beads with a diameter of 100 pm, which could introduce a rate limit for the mass transfer of factor VI11 from solution to the Sepharose surface and thereby influence the rate of association. To evaluate this possibility, we performed association experiments with different densities of vWF bound to RU 1 -Sepharose. Identical values were found for the rate constant of association, indicating that the observed rate constants reflect intrinsic kinetics and are unaffected by transport limitations.
The porous structure of the Sepharose beads, with a 20 X 10' Dalton exclusion size of the pores, also could present a point of concern with respect to the accessibility for factor VI11 binding. Our equilibrium binding data show that all vWF monomers are accessible for factor VI11 binding. In addition, no apparent deviations from the simple bimolecular association model were found in measurements of the association and dissociation kinetics. More convincingly, restricted accessibility could only be anticipated for low molecular vWF multimers, with molecular dimensions similar to factor VIII, whereas our data in Table 1 show that the kinetics observed for low and high multimers are not significantly different.
The site of complex formation between factor VI11 and vWF in the human body is not precisely known. The liver is the major site of factor VI11 synthesis, as shown by immunochemical localization studies,2R whereas vWF is synthesized by vascular endothelial cells' and megakaryocytes.' Interestingly, hepatic sinusoidal endothelial cells do not contain vWF:Ag' or Weibel-Palade bodies," which suggests that these cells are different from their vascular counterparts in that they do not synthesize vWF. Directly after synthesis and secretion, factor VI11 enters the space of Disse, the narrow space between the hepatocyte and the endothelium lining the sinusoid." The endothelium of the hepatic sinusoids contains fenestrations with openings up to 1 pm'" that permit plasma vWF to gain access to the surface of the hepatic cells. Thus, complex formation most likely occurs in the liver in the space of Disse, where factor VI11 and vWF first meet. The rate of complex formation, expressed as the halftime for complex formation, can be calculated as tlir = ln2/ (kc>" x vWF concentration + kc,ff). Based on the plasma concentration of vWF (50 nmol/L. in monomers),' together with the estimates for k,, and k,,, obtained in this study, the time needed to bind 50% of factor VlII is approximately 2 seconds.
The results obtained in the present work also provide L\ theoretical basis for the successful treatment of patients with hemophilia A with factor VI11 concentrates presently available. Since the 1970s, therapy in patients with severe hemophilia A depended on cryoprecipitates, a product that retains the normal amount and distribution of vWF multimers observed in plasma. However, during the period from 1980 to 1990, monoclonally purified and recombinant factor VI11 concentrates became available, and those products have become the standard in the treatment of patients with hemophilia A.''." However, it should be noted that these concentrates contain little or no vWF, and therefore factor VI11 is dependent on endogenous vWF with which it has to form a For personal use only. on September 14, 2017. by guest www.bloodjournal.org From complex to be protected against proteolytic degradation in plasma. Although clinical studies have proven that the plasma half-life of monoclonally purified and recombinant factor VI11 is not substantially different from that of less pure concentrate^,".^^ the time needed for complex formation between infused factor VI11 and endogenous vWF was heretofore unknown. Our results show that vWF from patients with hemophilia A resembles normal vWF with respect to factor VI11 binding kinetics. Moreover, infused factor VI11 is bound rapidly to the plasma vWF, with more than 95% binding in 12 seconds, which is extremely rapid in comparison to the half-life of 1 hour observed for factor VI11 in the absence of vWF in plasma. 33 Rapid complex formation may also serve to promote stable assembly of factor VI11 subunits at the site of secretion,34 or to prevent factor VI11 from interacting with components that bind with lower affinity, such as factor IXa (Kd = 15 n m~l / L ) '~ and phospholipids (Kd = 2 to 4 n m~l / L ) .~~ Previous studies have established that factor VI11 can be activated by factor Xa during the initial phase of factor X activation. Because factor VI11 bound to vWF is protected from activation by activated factor X,I5 rapid complex formation between factor VI11 and vWF may be important in regulating factor VI11 activity by inhibiting this feedback activation of factor VIII.
In summary, the kinetic experiments in this study show that factor VI11 forms a complex with vWF in plasma, with a half-life of complex formation of 2 seconds. This rapid complex formation between vWF and factor VIII, either in the liver or after infusion of factor VI11 in patients with hemophilia A, may be important in the stabilization and regulation of factor VI11 activity in plasma.
